dupa,
Don’t miss this conversation. The Endpoints 100.
The Trump administration may think that its policy on "most favored nation" drug pricing will bring costs down in the U.S., but the biotech industry is bracing for some entirely unintended consequences.
Check out what the C-suite is thinking about MFN in our upcoming panel discussion with Chris Garabedian, Marianne De Backer and Zhen Su at noon ET on Thursday, June 25.
We’ll check up on the industry’s attitudes on fundraising (more and more upbeat), the FDA (let’s fix it), China (there’s a silver lining) and much more, along with our regular look at hiring and other key business issues.
